- Ryan Keeling, Chief Innovation Officer at Diaceutics, has been listed as a life sciences industry leader in the annual PharmaVOICE 100
- PharmaVOICE recognised his commitment to resolving critical issues in diagnostic testing, which often prevent patients from receiving precision medicine therapies
- Keeling is currently leading the launch of Diaceutics’ new platform, DXRX – the world’s first diagnostic network for precision medicine
- for precision medicines
Belfast, Friday 14 August 2020 – Diaceutics today announces that its Chief Innovation Officer, Ryan Keeling, has been listed as a life sciences industry leader in the prestigious PharmaVOICE 100. Keeling was recognised by PharmaVOICE for his commitment to helping more patients get access to precision medicine drugs by resolving issues with diagnostic testing.
PharmaVOICE is a monthly publication covering news and developments in the global pharmaceutical industry. Its annual PharmaVOICE 100 list highlights the people whose leadership and innovative thinking are helping to transform the life sciences industry.
Keeling was credited by PharmaVOICE for his ‘fearless approach’ to technology in order to improve the impact of precision medicine drugs. In the early days of Diaceutics, Ryan was a driving force behind what has now become the world’s largest repository of diagnostic testing data. Diaceutics’ data lake brings together more than 2,500 labs in 51 countries covering 298 diseases, to help key stakeholders in precision medicine understand the diagnostic testing ecosystem and where the hurdles and opportunities lie with regard to getting every patient the treatment they deserve.
The global data repository will underpin Diaceutics’ DXRX platform, the world’s first diagnostic network for precision medicine, being pioneered by Keeling and set for launch in Q4 2020. The network will enable all precision medicine stakeholders to collaborate on one platform to improve testing efficiency and ensure that the right treatments get to the right patients at the right time. Last month, Diaceutics announced a major contract win for DXRX with a global pharmaceutical company to support its ground-breaking work in the field of immunotherapy.
Diaceutics’ founder and CEO, Peter Keeling, said: “From the very early days of Diaceutics, Ryan has channelled his passion and remarkable knowledge to consistently push boundaries in pursuit of the company’s mission to ensure no patient is left behind. He has been instrumental in all of our greatest achievements, including our flotation on the AIM market of the London Stock Exchange in March last year. I am delighted that Ryan has been recognised for his achievements by such a prestigious publication and look forward to an exciting end to the year when we launch our DXRX platform.”